FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement [Yahoo! Finance]
FibroBiologics, Inc. (FBLG)
Company Research
Source: Yahoo! Finance
HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026, with trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading on Monday, March 30, 2026 under the Company's existing ticker symbol, “FBLG.” At the effective time, every 20 shares of FibroBiologics' issued and outstanding common stock will automatically be combined into one share of common stock. The reverse stock split will reduce the number of shares of the Company's outstanding com
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics (FBLG) had its "hold" rating reaffirmed by D. Boral Capital.MarketBeat
- FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price RequirementGlobeNewswire
- FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.MarketBeat
- FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid TechnologyGlobeNewswire
- FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot UlcersGlobeNewswire
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Analyst Actions
- 2/26/26 - HC Wainwright
FBLG
Sec Filings
- 3/27/26 - Form S-1
- 3/13/26 - Form 10-K/A
- 3/6/26 - Form 8-K
- FBLG's page on the SEC website